LYON, France, November 19, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced a moderated scientific presentation of clinical data comparing Focal ...

A study from Karl Landsteiner University of Health Sciences demonstrates that treatment with focused ultrasound (HIFU) effectively controls prostate cancer and maintains patients’ quality of ...

The first prostate ablation treatment with the Ablatherm Robotic HIFU was performed at the Gramercy Surgery Center in New York. 1. Ivan Grunberger, MD, chief of urology at New York Methodist Hospital ...

One in eight men will develop prostate cancer in their lifetime. Surgery to treat the disease can lead to unwelcome side effects. A minimally invasive alternative that avoids surgery is now available ...

The Fred Hutchinson Cancer Center recently added irreversible electroporation (IRE) to its slate of focal therapy offerings and is the only cancer center in the region to offer IRE, high-intensity ...

HIFI Study is the largest (N = 3,328) prospective, comparative, multi-center clinical study ever conducted comparing prostate cancer treatments Positive study results are expected to drive further ...

Dr. Benjamin Waldorf, Erlanger urologist, performed his first noninvasive Focal One Robotic High Intensity Focused Ultrasound (HIFU) procedure for prostate cancer on Aug. 17. "Erlanger Urology, a ...

Webcast scheduled for Tuesday, April 18th at 12:00 p.m. PDT (3:00 p.m. EDT) LYON, France, April 10, 2023-- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies ...

Treatment with robotic HIFU showed reduction in moderate and severe post-operative complications and reduced hospital stay compared to surgery “The comparative results from these two cohorts ...

Treatment with robotic HIFU showed reduction in moderate and severe post-operative complications and reduced hospital stay compared to surgery LYON, France, November 19, 2024 - EDAP TMS SA (Nasdaq: ...